Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E17.20 EPS (ttm)15.34 Insider Own0.10% Shs Outstand222.90M Perf Week-3.37%
Market Cap58.81B Forward P/E13.23 EPS next Y19.95 Insider Trans138.55% Shs Float222.68M Perf Month-10.15%
Income3.55B PEG1.77 EPS next Q4.43 Inst Own91.20% Short Float1.28% Perf Quarter-11.03%
Sales10.76B P/S5.46 EPS this Y24.00% Inst Trans-0.04% Short Ratio1.54 Perf Half Y-16.66%
Book/sh42.54 P/B6.20 EPS next Y7.81% ROA19.60% Target Price360.24 Perf Year-34.33%
Cash/sh15.38 P/C17.15 EPS next 5Y9.73% ROE32.10% 52W Range254.00 - 480.18 Perf YTD-13.87%
Dividend- P/FCF- EPS past 5Y31.20% ROI20.20% 52W High-45.05% Beta0.96
Dividend %- Quick Ratio2.30 Sales past 5Y17.90% Gross Margin88.50% 52W Low3.88% ATR10.68
Employees7550 Current Ratio2.60 Sales Q/Q7.50% Oper. Margin45.40% RSI (14)43.06 Volatility3.53% 4.11%
OptionableYes Debt/Eq0.97 EPS Q/Q0.80% Profit Margin33.00% Rel Volume1.55 Prev Close273.27
ShortableYes LT Debt/Eq0.70 EarningsJan 27 BMO Payout0.00% Avg Volume1.85M Price263.86
Recom2.00 SMA20-2.83% SMA50-7.25% SMA200-19.08% Volume2,856,429 Change-3.44%
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Feb-05-16 02:52PM  Biogen (BIIB) Stock Gets Market Perform Rating at Leerink at TheStreet
11:55AM  Three things Biogen is more worried about this year than it was in 2015 at bizjournals.com
10:32AM  Leerink Is Back On Board The Biotech Train
08:00AM  Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma Accesswire
Feb-04-16 04:01PM  Biogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference Business Wire
02:29PM  Its Time to Buy This Biotech Gem
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink
Feb-03-16 04:30PM  BIOGEN INC. Files SEC form 10-K, Annual Report
02:53PM  The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors
10:08AM  How Much Does Biogen Spend on Research and Development?
08:28AM  Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
08:10AM  Insight into the Performance of Interferon and Other Products
Feb-02-16 05:00PM  Biogen Inc. Slows (But Let's Keep This in Perspective) at Motley Fool
04:33PM  Gilead: 4Q EPS, Revenue Beat at Barrons.com
03:44PM  Tecfidera Raised Its Share of Contribution to Overall Revenue
03:43PM  Biogen Announced Its 4Q15 Earnings: EPS Beat Estimates
03:39PM  Health care analyst: How to play the current biotech market ahead of earnings
11:19AM  Start the New Year off Right with 3 Best Biotech Stocks at Motley Fool
Feb-01-16 04:51PM  Two ETF Plays for a Rebound in Biotech Stocks at TheStreet
12:03PM  Jim Cramer's Long-Term View on Health Care Stocks at TheStreet
09:50AM  The 4 Largest Biotech Stocks Are Cheaper Than S&P 500 at 24/7 Wall St.
12:04AM  What Does Novartis Expect from Pharmaceuticals?
Jan-30-16 08:05AM  Vertex Will Focus on Cystic Fibrosis Market in 2016
Jan-29-16 04:06PM  Regeneron Continues to Trade at Premium
08:59AM  Biotech ETF (IBB) Hits New 52-Week Low
08:39AM  Maybe Some Good News For A Big Biotech ETF
Jan-28-16 02:05PM  Bargains Anyone? Big-Cap Biotech Stocks Plumb Lowest Valuations in 10 Years at Barrons.com
12:00PM  Biogen's Chart Shows Shares Could Turn Bullish
12:00PM  Biogen (BIIB) Stock is the 'Chart of the Day' at TheStreet
11:25AM  Biogen, Inc. Earnings Analysis: Q4, 2015 By the Numbers
10:10AM  Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now at 24/7 Wall St.
08:35AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
08:00AM  Biogen (BIIB) Looks Good: Stock Adds 5.2% in Session
02:01AM  Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleeding rates with long-term Elocta® treatment GlobeNewswire
12:46AM  [$$] Biogen: Clearing a Lower Biotech Bar at The Wall Street Journal
12:45AM  [$$] Biogen Results Top Views as Sales of MS Drug Grow at The Wall Street Journal
Jan-27-16 11:25PM  [$$] Biogen: Big Upside for Beaten-Down Biotech at Barrons.com +5.15%
06:27PM  Why Biogen, Freeport-McMoRan, and Hawaiian Holdings Jumped Today at Motley Fool
05:17PM  Earnings Recap For January 27
04:06PM  Stocks Churning As Street Absorbs Dovish Fed Remarks
03:08PM  Stocks sink after Fed statement; Facebook earnings after hours
02:38PM  Edited Transcript of BIIB earnings conference call or presentation 27-Jan-16 1:30pm GMT
02:16PM  Stocks Slide as Fed Tempers Outlook at TheStreet
12:46PM  Biogen: That's a Lot of Waiting at Barrons.com
12:44PM  3 Stocks, 3 trades: HES, BIIB, & BA
12:44PM  [$$] Biogen: Clearing a Lower Biotech Bar at The Wall Street Journal
11:59AM  Jim Cramer: Biogen (BIIB) Reported 'Monstrous' Top and Bottom Line Beat at TheStreet
11:50AM  Biogen still has a huge pile of cash, paving the way for M&A at bizjournals.com
11:41AM  Assume No More Biogen Drug Price Hikes? Not So Fast at TheStreet
11:35AM  Biogen Tops on Q4 Earnings by a Wide Margin, Provides View
11:15AM  Biogen Averts Worst Case With Q4 Earnings Beat, In-Line Guidance
10:58AM  [$$] Biogen Results Top Expectations at The Wall Street Journal
10:28AM  Biogen 4Q profit falls on costs, but tops forecasts
09:55AM  Apple worries; Boeing loses altitude; Biogen blasts off
09:25AM  Biogen (BIIB) Beats on 4Q Earnings & Revenues
09:15AM  How Anthem Fell Short on Earnings and Membership at 24/7 Wall St.
08:37AM  Biogen's Stock Pops Following Better-Than-Expected Q4 Results
08:35AM  How Biogen Won at Earnings in Q4 at 24/7 Wall St.
07:54AM  Novartis profits plunge
07:44AM  Biogen 2015 Revenues Increase 11% to $10.8 Billion at noodls
07:40AM  Wall St awaits Fed; Apple iPhone sales slow; Trump's Twitter vs. TV
07:29AM  Biogen's stock surges after profit, sales beat at MarketWatch
07:28AM  Biogen's quarterly sales rise 7.5 percent
07:28AM  Biogen's Top Drug Has Record Quarter, Beats Estimates at Bloomberg
07:21AM  BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:15AM  Biogen 2015 Revenues Increase 11% to $10.8 Billion Business Wire
07:07AM  Q4 2015 Biogen Inc Earnings Release - Before Market Open
Jan-26-16 02:29PM  What to Watch in the Day Ahead - Wednesday, Jan 27 Reuters
01:50PM  What to Expect From Biogen Earnings
12:30PM  Earnings trade Ideas in Biogen Idec
11:00AM  Biogen: No Cure In Sight For Slow Growth
09:20AM  Celgene (CELG) to Report Q4 Earnings: What to Expect?
07:26AM  AbbVie in 4Q15: Analysts Project Strong Revenue Growth
Jan-25-16 04:50PM  Will Biogen (BIIB) Beat 4Q Earnings on MS Franchise Sales?
04:42PM  Relypsa Results Surprise Wall Street
01:03PM  Biotech String: Editas IPO Terms, Rooting for Shkreli in DC at TheStreet
11:50AM  5 Big-Cap Drugmakers Reporting Q4 Earnings This Week; J&J First
10:07AM  Celgenes Valuation Is Higher Than Its Peers
07:50AM  Investors look to Biogen earnings this week to pull sector out of slump at bizjournals.com
06:45AM  Goldman: Here are the stocks to buy if you fear a U.S. recession at MarketWatch
Jan-24-16 04:55PM  Big Earnings Expectations For Big Biotech
Jan-22-16 11:07AM  Pomalyst and Abraxane Revenues Are Critical for Celgene
Jan-21-16 06:53PM  How the Vanguard PRIMECAP Fund Performed in 2015
08:05AM  AbbVie Trades at Discounted Valuations Compared to Its Peers
Jan-20-16 03:50PM  Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie
11:07AM  10 Biotech Buys from Credit Suisse at Barrons.com
06:12AM  Coverage initiated on Biogen by Credit Suisse
Jan-19-16 12:29PM  Biotech: Will Earnings Help? at Barrons.com
12:01PM  The Biotech Gem Institutions are Hiding
08:39AM  Biogen Ticks Up Following EU Marketing Authorization Of Benepali
08:20AM  Are These the Top Biotech Stocks of 2016? at Investopedia
Jan-18-16 03:10PM  Biogen's (BIIB) Biosimilar of Amgen's Enbrel Gets EU Nod
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Cytokinetics and Bristol-Myers Squibb
Jan-16-16 09:05PM  BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union Business Wire
09:00PM  Samsung Bioepis Enters the European Biopharmaceutical Market with Benepali®, the First Fusion Protein Biosimilar Approved by the European Commission Business Wire
12:00PM  AbbVie's Management Just Made Some Pretty Bold Predictions at Motley Fool
10:10AM  10 biotech stocks to buy at silly cheap prices at MarketWatch
Jan-15-16 03:31PM  Biotech in bear market
12:01PM  4 Biotech Stocks Looking Good this Earnings Season
11:04AM  Biogen's CEO Sums Up Everything You Need to Know About the Company in 1 Comment at Motley Fool
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company has a strategic partnership with BioMotiv, LLC. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM
DENNER ALEXANDER JDirectorOct 23Buy276.77100,00027,677,000310,000Oct 26 07:03 PM
DENNER ALEXANDER JDirectorOct 22Buy277.80210,00058,338,000210,000Oct 26 07:03 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 05Sale291.4326978,3958,094Oct 06 04:40 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 02Sale283.38417118,1698,363Oct 05 04:10 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 01Option Exercise0.001,939010,446Oct 05 04:10 PM
PAPADOPOULOS STELIOSDirectorJul 27Buy304.8810,0003,048,7755,000Jul 27 05:03 PM
Posner Brian SDirectorJun 22Sale415.00470195,0505,275Jun 23 04:14 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentJun 19Sale410.003,8411,574,81011,817Jun 22 04:15 PM
Posner Brian SDirectorJun 15Sale386.64400154,6565,745Jun 16 06:54 PM
Koppel AdamSVP, Chief Strategy OfficerJun 02Option Exercise0.002,38402,514Jun 04 05:49 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale398.871,362543,26141,090Jun 02 04:10 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise386.22347134,0181,874May 05 04:36 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale377.521,362514,18242,452May 05 04:34 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,134Apr 03 04:24 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale423.201,362576,39843,814Apr 02 04:29 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM